OXIS International, Inc. (OXIS) Licenses Lead Compound To HaptoGuard Inc.; BXT-51072, Phase II Compound, To Be Developed For Cardiovascular Diseases
10/19/2005 5:09:18 PM
OXIS International, Inc. (OTCBB:OXIS) (Nuveau Marche:OXIS) today announced that a worldwide exclusive license agreement has been signed with HaptoGuard Inc. for BXT-51072 and related compounds for cardiovascular indications. HaptoGuard will seek to develop and commercialize OXIS' lead glutathione peroxidase mimic, BXT-51072, for indications ranging from acute coronary syndromes and atherosclerosis to stroke.
comments powered by